頭蓋内腫瘍における血漿中,髄液中および嚢胞液中carcinoembryonic antigenの臨床的意義について
スポンサーリンク
概要
- 論文の詳細を見る
Carcinoembryonic antigen (CEA) in plasma, cerebrospinal fluid (CSF) and cystic fluid of patients with various intracranial tumors were determined by a radioimmunoassay using Dainabot and Roche CEA Kits.Slightly elevated levels of plasma CEA were noted in 6 (4%) out of 161(6/161) patients with primary brain tumors:gliomas, 3/67;pituitary adenomas, 0/30; meningiomas, 0/28; acoustic neurinomas, 1/12;pineal tumors, 2/12 (germinomas, 1/8;teratoma, 0/1;teratoblastoma, 0/1;embryonal carcinoma, 1/1;not verified histologically, 0/1); craniopharyngiomas, 0/6; hemangioblastomas, 0/2; epidermoid tumor, 0/1;reticulum cell sarcoma, 0/1;choroid plexus papilloma, 0/1; chondroma, 0/1.The plasma CEA levels of these 6 patients varied from 2.6 to 3.8 ng/ml.On the other hand, 17(37%) out of 46 patients with metastatic brain tumor showed definite elevation of CEA levels in plasma and most of them showed values higher than 5.1 ng/ml ranging from 3.0 to 2,317 ng/ml.CEA in CSF of 55 patients woth intracranial tumor were determined.Since CEA levels in CSF obtained from 38 control subjects were mostly 0 ng/ml, ranging from 0 to 0.5 ng/ml, an upper limit of normal CEA level in CSF by one step sandwich method was proposed tp be 0.5 ng/ml.Significant elevation of CEA levels in CSF was noted in the one of 37 patients with primary brain tumors, a patient with pineal germinoma showing a spinal metastasis, and in 8 (44%) out of 18 patients with metastatic brain tumor.All of 6 patients woth leptomeningeal carcinomatosis showed elevated levels of CEA in CSF.CEA in cystic fluid were measured in 17 patients with intracranial tumors, including 12 gliomas, 2 craniopharyngiomas, 2 metastatic brain tumors and 1 meningioma.Elevated levels of the tumor fluid CEA were noted in 2 patients with craniopharyngioma (8.6 ng/ml and 11.0 ng/ml, respectively ) and in one with metastatic brain tumor from breast cancer (14300 ng/ml).Mean value of the tumor fluid CEA of 12 glioma patients was 0.6+0.6g/ml.A meningioma and one metastatc tumor showed low levels of CEA less than 0.5ng/ml in the tumor fluids.Study on sequential determination of CEA in plasma or CSF performed on three patients revealed that CEA levels were well correlated with the activity of the tumotrs and could be used for evaluation of treatment of foreknowledge of recurrence of tumors.In conclusion, determination of CEA in plasma or CSF is valuable for differential diagnosis between primary and metastatic brain tumors, evaluation of treatments, or fore-knowledge of recurrence of tumors.Determination of CEA in CSF could be very useful especially for diagnosis of diagnosis of leptomeningeal carcinomatosis.
- 日本脳神経外科学会の論文
- 1979-11-15
著者
関連論文
- 悪性脳腫瘍の高周波温熱療法に関する研究 : 1.皮下移植実験脳腫瘍に対する効果
- 転移性脳腫瘍に対する放射線治療の評価 : CTによる効果判定
- ヒト glioma 由来株化細胞の DNA含量と ACNU感受性
- 悪性脳腫瘍に対するbleomycin,ACNU,vincristine併用照射療法 : 腫瘍縮小効果について
- 悪性脳腫瘍の局所的免疫療法 : BCGおよび溶連菌製剤の腫瘍内投与の意義について
- CTによる髄芽腫の放射線感受性の評価と再発部位
- 大脳悪性神経膠腫の治療後の反応と再発育に関する研究 : 再発腫瘍のCT上の進展形式
- 大脳悪性神経膠腫の治療後の反応と再発育に関する研究 : 放射線化学療法後のCT上の反応
- 243 非小細胞肺癌切除後の脳転移治療例の検討
- 実験脳腫瘍に対するACNUの抗腫瘍効果
- 頭蓋内腫瘍における血漿中,髄液中および嚢胞液中carcinoembryonic antigenの臨床的意義について